Wilson MR, Gutierrez B, Offord S, Blanchette CM, Eramo A, Earnshaw SR, Kamat SA. Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Drugs Context. 2016 Mar 11;5:212273. doi: 10.7573/dic.212273
Kamat SA, Blanchette C, Wilson MR, Tangirala M, Earnshaw SR, Offord S, Gutierrez B, Eramo A, Baker RA. Healthcare cost savings associated with aripiprazole once-monthly (AOM) treatment among schizophrenia patients with psychiatric hospitalizations prior to AOM treatment initiation. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 3, 2014.
Wilson MR, Gutierrez B, Offord S, Zhao C, Beillat M, Eramo A, Earnshaw SR. Total healthcare cost-offset associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia. Poster presented at the US Psychiatric & Mental Health Congress; September 2013.
Earnshaw SR, Beard SM, Gaffney L, Krishnan A, Hogue SL. The impact of premature discontinuation of antidepressant therapy in major depressive disorder in the UK. Poster presented at the 2004 ISPOR 7th Annual European Congress; October 24, 2004. [abstract] Value Health. 2004 Nov; 7(6):A779.
Earnshaw SR, Krishnan A, Hogue SL, Williams JW. The impact of premature discontinuation of antidepressant therapy in major depressive disorder. Poster presented at the 2004 ISPOR 9th Annual International Meeting; May 16, 2004. Arlington, VA. [abstract] Value Health. 2004 May; 7(3):267.
Alexeyeva I, Mauskopf JA, Earnshaw SR, Gibson JP, Ascher-Svanum H, Ramsey J. A model comparing olanzapine and ziprasidone in patients with schizophrenia. Poster presented at the 2001 ISPOR 6th Annual International Meeting; May 2001. [abstract] Value Health. 2001 Sep; 4(2):148-9.
Alexeyeva I, Mauskopf J, Earnshaw SR, Stauffer VL, Gibson JP, Ascher-Svanum H. Comparing olanzapine and ziprasidone in the treatment of schizophrenia: a case study in modeling. J Med Econ. 2001 Jan 1;4:179-92.